Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
NCT06857240Phase 2Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Jun 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in dermatomyositis (DM), sponsored by Cleveland Clinic. Primary endpoint: Cutaneous Dermatomyositis Disease Area and Severity Index at 8 weeks. Started Jun 2025; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT06857240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857240.